Press release – Transgene

Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201027 - TG4001+avelumab abstract data SITC - EN

By @CcR34Tg|2020-10-26T18:53:22+01:00October 27th, 2020|Press release, TG4001, TG4001|Comments Off

20201019 TG4001+avelumab SITC - EN

By nh|2020-10-16T16:20:03+02:00October 19th, 2020|Press release, TG4001, TG4001|Comments Off

20201015 - BT-001_SITC poster EN

By nh|2020-10-14T16:19:05+02:00October 15th, 2020|BT-001, BT-001, Press release|Comments Off

20201006 Transgene_NEC_BostonGene_Press_Release_final

By nh|2020-10-05T16:58:26+02:00October 6th, 2020|Myvac, Press release, TG4050|Comments Off

20200916 Results H1 2020 EN

By nh|2020-09-16T16:44:44+02:00September 16th, 2020|Press release|Comments Off

20200909 Next investor events

By nh|2020-09-09T16:03:35+02:00September 9th, 2020|Press release|Comments Off

20200908 Transgene TG6002 Phase 1 EN

By nh|2020-09-08T16:07:44+02:00September 8th, 2020|Invir.IO, Press release, TG6002, TG6002|Comments Off

20200804 Transgene - Partial sale Tasly Shares EN

By nh|2020-08-04T16:32:49+02:00August 4th, 2020|Press release|Comments Off

CP TG4001+avelumab EN - Vdef-

By nh|2020-07-22T16:30:04+02:00July 22nd, 2020|Press release, TG4001, TG4001|Comments Off

20200709 PR Hypertrust Transgene EN

By nh|2020-07-08T18:29:33+02:00July 9th, 2020|Myvac, Press release, TG4050|Comments Off